Multiple System Atrophy clinical trials at UC Irvine
3 research studies open to eligible people
GDNF Gene Therapy for Multiple System Atrophy
open to eligible people ages 35-75
The objective of this randomized, double-blinded, placebo-controlled Phase 1 investigation is to evaluate the safety and potential clinical effect of AAV2-GDNF delivered to the putamen in subjects with either a possible or probable diagnosis of Multiple System Atrophy.
Irvine, California and other locations
Parkinson's And Zoledronic Acid
open to eligible people ages 60 years and up
This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 3500 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the National Institute of Aging.
Irvine, California and other locations
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
open to eligible people ages 35-75
The objective of this study is to describe disease progression in study participants diagnosed with early Parkinson's Disease or Multiple System Atrophy - Parkinsonian Type up to 18 months as delineated by clinical and biochemical parameters.
Irvine, California and other locations
Our lead scientists for Multiple System Atrophy research studies include Nicolas Phielipp, MD.
Last updated: